NASDAQ:CLVR - Nasdaq - CA1867602031 - Common Stock - Currency: USD
CLEVER LEAVES HOLDINGS INC
NASDAQ:CLVR (5/16/2024, 8:00:00 PM)
After market: 3.05 +0.05 (+1.67%)3
+0.89 (+42.18%)
The current stock price of CLVR is 3 USD. In the past month the price decreased by -26.74%. In the past year, price decreased by -60.1%.
Colombia's cannabis decree allows dry flower sales, but ex-official claims it won't just protect small producers—most companies may qualify.
Several cannabis companies faced delisting in 2024, including Bright Green and Aurora, due to financial struggles. Learn what happened here..
Cannabis stocks are soaring amid potential rescheduling of the drug. But these three cannabis stocks are still in deep trouble regardless.
Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday!
TOCANCIPÁ, Colombia, April 26, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a...
CLVR stock results show that Clever Leaves Holdings missed on revenue for the fourth quarter of 2023.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.56 | 833.80B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.18 | 383.72B | ||
JNJ | JOHNSON & JOHNSON | 15.33 | 368.65B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 19.94 | 223.25B | ||
MRK | MERCK & CO. INC. | 11.42 | 220.79B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.55 | 212.44B | ||
PFE | PFIZER INC | 8.28 | 145.87B | ||
SNY | SANOFI-ADR | 13.44 | 133.76B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 49.87 | 115.30B | ||
ZTS | ZOETIS INC | 29.76 | 77.34B | ||
GSK | GSK PLC-SPON ADR | 7.82 | 73.53B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.75 | 42.89B |
Clever Leaves Holdings Inc is a CO-based company operating in Pharmaceuticals industry. The company employs 400 full-time employees The company went IPO on 2020-12-18. Clever Leaves Holdings Inc. is a multinational operator and licensed producer of pharmaceutical-grade cannabinoids. The firm's segments include Cannabinoid and Non-Cannabinoid. The Cannabinoid segment is comprised of cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products. The Non-Cannabinoid operating segment is comprised of the brands and manufacturing assets acquired as part of its acquisition of Herbal Brands. The Non-Cannabinoid segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing wellness products and nutraceuticals, excluding cannabinoid products. Its customers for the Herbal Brands products include specialty and health retailers, mass retailers and specialty and health stores in the United States. The company offers product portfolio in two categories: nutraceuticals and cannabinoids. The nutraceutical products consist of a variety of beverage and powder products.
CLEVER LEAVES HOLDINGS INC
Bodega 19-B Parque Industrial Tibitoc Ph, Tocancipa - Cundinamarca
Boca Raton FLORIDA 10017 CO
CEO: Kyle Detwiler
Employees: 400
Company Website: https://cleverleaves.com/
Phone: 16468804382.0
The current stock price of CLVR is 3 USD.
The exchange symbol of CLEVER LEAVES HOLDINGS INC is CLVR and it is listed on the Nasdaq exchange.
CLVR stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CLVR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CLVR.
CLVR does not pay a dividend.
CLVR will report earnings on 2024-08-12, after the market close.
CLVR does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.4).
The outstanding short interest for CLVR is 0.55% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to CLVR. Both the profitability and financial health of CLVR have multiple concerns.
Over the last trailing twelve months CLVR reported a non-GAAP Earnings per Share(EPS) of -11.4. The EPS decreased by 78.15% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -57.31% | ||
ROE | -73.94% | ||
Debt/Equity | 0.03 |
ChartMill assigns a Buy % Consensus number of 43% to CLVR. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 29.03% and a revenue growth 50% for CLVR